ni006
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 10, 2020 (NCT04360434)
Timeline
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213583 | Phase 2 | Aug 28, 2025 | Alexion, Neurimmune AG |
| NCT06183931 | Phase 3 | Jan 4, 2024 | Alexion |
| NCT04360434 | Phase 1 | Feb 10, 2020 | Neurimmune AG |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexion | For profit | 2 | 1 | 2 | 2024 |
| Neurimmune AG | For profit | 2 | 2 | 2 | 2020 |
2 organizations
Page 1 / 1